Korsana Biosciences, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for neuropsychiatric and neurodegenerative disorders. The company’s lead program, CYC-126, is an anesthetic-based therapy for treatment-resistant depression that utilizes propofol and dexmedetomidine with a technology-enabled delivery system to monitor brain activity and support individualized dosing. Korsana is also advancing KRSA-028, a precision-engineered therapeutic for Alzheimer’s disease, leveraging the Therapeutic Targeting (THETA) platform developed in partnership with Paragon Therapeutics to enhance central nervous system exposure. The company was formed through the merger of Cyclerion Therapeutics and Korsana Biosciences, combining Cyclerion’s neuropsychiatric pipeline with Korsana’s blood-brain barrier shuttle technology. Korsana holds a license agreement with the Massachusetts Institute of Technology for intellectual property supporting CYC-126 and a collaboration agreement with Medsteer SAS for drug delivery and physiological monitoring technology. The company plans to initiate a Phase 2 proof-of-concept study for CYC-126 in Australia in the second half of 2026, with U.S. enrollment expected in the first half of 2027.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage korsana.com
Sector Healthcare IR page investors.korsana.com
Tags
neuropsychiatric disorders, treatment-resistant depression, alzheimer's disease, blood-brain barrier penetration, anesthetic-based therapy, drug delivery, eeg monitoring, precision medicine, CYC-126, KRSA-028, THETA, Cyclerion Therapeutics, Paragon Therapeutics, Medsteer SAS, Massachusetts Institute of Technology, zagociquat, CY3018, praliciguat, olinciguat
Press page —

Metrics

Valuation  
Market cap —
Market cap (USD) —
P/E —
PEG —
P/BV —
P/S —
P/OCF —
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE —
ROI —
ROIC —
Profit margin —
Growth  
Revenue growing —
Profits growing —
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable —
Margin expanding —
Buying back stock —
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 8
Quality score —
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure Q3 2026 Q4 2025* Q3 2025 Q4 2024* Q4 2023* Q4 2022* Q4 2021* Q4 2020* Q4 2019*
Revenue — 1.025M — — 0 608K 532K 133K —
Net profit -46.425M -799K -21.723M 530K -1.694M -7.216M -10.776M -19.228M -26.056M
Free cash flow -47.06M — — — — — — -14.076M -22.337M

Figure Q3 2026 Q4 2025* Q3 2025 Q4 2024* Q4 2023* Q4 2022* Q4 2021* Q4 2020* Q4 2019*
Share price 32 1.27 2.3 3.22 3.35 — 3.16 3.01 2.48
Price performance 12m — -0.61 -0.11 -0.04 — — 0.05 0.21 —

Filed figures

Figure Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — — 0.00 100,000 96,000 0.00 556,000 1M
↳ YoY growth -4.0% -100.0% +79.9%
Borrowings, current (USD) — — — 3.5M 3.5M 3.5M — — —
Lease liabilities (USD) — — 73.9M 42.2M 0.00 — — — 0.00
Cash and deposits (USD) 0.00 0.00 94.9M 54.4M 54M 13.4M 7.57M 3.23M 3.24M
Right-of-use assets (USD) — — 68.1M 43.4M 1.4M 1.22M 0.00 — 0.00
Net debt (borrowings + leases - cash) (USD) — — — -8.67M -50.5M -9.88M — — —
Cash flow detail
Operating cash flow (USD) — -97.5M -102M -72.5M -36.5M -40.6M -21.2M -4.33M -3.31M
Purchases of property, plant and equipment (USD) — -3.44M -6.89M -1.52M -7,000 0.00 — — —
Change in receivables (cash effect) (USD) — — — 0.00 100,000 4,000 96,000 -556,000 -444,000
Share-based compensation (USD) — 12.4M 19.6M 15M 9.61M 6.25M 1.07M 625,000 441,000
Operating cash flow before change in receivables (USD) — — — -72.5M -36.6M -40.6M -21.3M -3.78M -2.87M
Free cash flow (OCF - PPE - intangibles) (USD) — -101M -109M -74M -36.5M -40.6M — — —
Income detail
Research and development expense (USD) — 87.7M 95.1M 56.4M 37.6M 31.5M 1.52M 286,000 959,000
↳ 5y CAGR -55.6% -68.7% -55.7%
Total comprehensive income (USD) — -115M -123M -77.8M -51.6M -44.1M -5.26M -3.06M -3.53M
Reported May 13, 2019 Mar 12, 2020 Mar 12, 2020 Feb 24, 2022 Feb 24, 2022 Mar 22, 2023 Mar 5, 2024 Mar 4, 2025 Nov 5, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Phase 1 healthy volunteer data for KRSA-028 expected mid-2027 and interim proof-of-concept data in Alzheimer’s disease patients anticipated by year-end 2027 or first quarter of 2028

Cash and cash equivalents of approximately $456.2 million as of

September 30, 2026, expected to fund operations into 2029

WALTHAM, Mass., November 5, 2026— Korsana Biosciences, Inc. (“Korsana” or the “Company”) (Nasdaq: KRSA), a biotechnology company discovering and developing novel therapies to reduce the burden of neurodegenerative diseases, today reported financial results for the third quarter ended September 30, 2026, and provided a corporate update.

“The third quarter was transformative for Korsana, providing us with the financial resources and experienced leadership team to execute our strategy,” said Jonathan Violin, Ph.D., President and Chief Executive Officer of Korsana.

September 8, 2026

PDF Version

Advancing lead program KRSA-028 toward the clinic, with Phase 1 healthy volunteer data expected mid-2027 and interim proof-of-concept data in Alzheimer’s patients anticipated by year-end 2027 or first quarter of 2028

Strong financial position with post-transaction cash and cash equivalents of approximately $475 million1 expected to fund operations into 2029

Shares to begin trading on Nasdaq under ticker symbol “KRSA” on September 9

WALTHAM, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Korsana Biosciences, Inc. (“Korsana” or the “Company”), a biotechnology company discovering and developing novel therapies to reduce the burden of neurodegenerative diseases, today announced the completion of its previously announced merger with Cyclerion Therapeutics, Inc. (“Cyclerion”). The combined company will operate under the name Korsana Biosciences, Inc., and its shares are expected to begin trading on the Nasdaq Capital Market on September 9, 2026, under the ticker symbol “KRSA.”

Immediately prior to the closing of the merger, Korsana completed a previously announced private financing of $380 million in gross proceeds from a syndicate of new and existing investors led by Fairmount and Venrock Healthcare Capital Partners, with participation from General Atlantic, TCGX, Forbion, Wellington Management, Commodore Capital, RA Capital Management, RTW Investments, Vivo Capital, Janus Henderson Investors, Foresite Capital, J.P. Morgan Life Sciences Private Capital, SR One, Sanofi Ventures, Kalehua Capital, Spruce Street Capital, and other leading investment management firms. The financing includes common stock and pre-funded warrants to purchase additional shares of common stock. This financing, together with existing cash, is expected to support the Company’s operations into 2029, including through multiple clinical milestones for KRSA-028.

Pursuant to the terms of the previously disclosed merger agreement, each outstanding share of Korsana common stock was converted into the right to receive approximately 0.2074 shares of common stock of the combined company, as adjusted for the reverse stock split of Cyclerion Therapeutics’ common stock at a ratio of 1-for-7 shares, effected immediately prior to the merger. The new CUSIP number for the combined company following the reverse stock split and merger is 23255M303. Following the completion of the reverse stock split, the private placement, and the merger, there are approximately 55.1 million shares of the combined company's common stock and common stock equivalents outstanding, including shares of common stock underlying pre-funded warrants and Series B convertible preferred stock, and excluding shares underlying equity awards.

“Today marks the beginning of an exciting new chapter for Korsana. With an exceptional team, a strong financial foundation supported by leading biotechnology investors, and a pipeline of differentiated therapeutic candidates, we are well positioned to execute on our long-term vision,” said Jonathan Violin, Ph.D., Korsana’s President and Chief Executive Officer. “As we advance KRSA-028 toward the clinic, we remain focused on our mission to reduce the burden of neurodegenerative diseases by bringing forward innovative therapies for patients and caregivers.”

KRSA-028 is an investigational, next-generation shuttled antibody targeting amyloid beta for the treatment of Alzheimer’s disease. KRSA-028 leverages the proprietary Therapeutic Targeting (THETA™) technology platform, which combines clinically validated transferrin receptor (TfR1) and Fc engineering and is designed to improve brain delivery, safety, and convenience. The Company is advancing KRSA-028 toward the clinic, with Phase 1 healthy volunteer data expected in mid-2027 and interim proof-of-concept data evaluating amyloid plaque clearance in Alzheimer’s disease patients anticipated by the end of 2027 or the first quarter of 2028.

About Korsana Biosciences Korsana Biosciences is committed to building best-in-class therapeutics with the goal of reducing the burden of neurodegenerative diseases for patients and caregivers. The Company’s lead program, KRSA-028, is a next-generation shuttled antibody targeting amyloid beta for the treatment of Alzheimer’s disease. KRSA-028 leverages Therapeutic Targeting (THETA™), a novel CNS shuttle technology developed in partnership with Paragon Therapeutics and designed to enable dramatically higher drug concentrations in the brain and overcome the limitations of earlier shuttle technologies. In addition, Korsana is advancing a pipeline of innovative therapies for neurodegenerative diseases. For more information, please visit www.korsana.com and follow the Company on LinkedIn.

Forward-Looking Statements

Certain statements in this press release, other than purely historical information, may constitute "forward-looking statements" within the meaning of the federal securities laws, including for purposes of the "safe harbor" provisions under the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements relating to Korsana’s expectations, hopes, beliefs, intentions or strategies regarding the future of its pipeline and business including, without limitation, Korsana’s ability to achieve the expected benefits or opportunities with respect to KRSA-028; the expected timelines of clinical data for KRSA-028; the potential benefits of the THETA technology platform; the sufficiency of the combined company’s cash, cash equivalents, and proceeds from the private placement to fund operations into 2029, including through multiple clinical milestones for KRSA-028; the expected number of shares of common stock and common stock equivalents outstanding following the transactions; and the timing of the combined company’s trading on the Nasdaq Capital Market with a new ticker symbol and CUSIP number. The words "opportunity," "potential," "milestones," "pipeline," "can," "goal," "strategy," "target," "anticipate," "achieve," "believe," "contemplate," "continue," "could," "estimate," "expect," "intends," "may," "plan," "possible," "project," "should," "will," "would" and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Korsana will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Korsana’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to those uncertainties and factors more fully described in Korsana’s most recent filings with the Securities and Exchange Commission (including the registration statement on Form S-4 (File No. 333-295175) filed by Cyclerion (now Korsana Biosciences, Inc.), as most recently amended on July 22, 2026 and declared effective by the SEC on July 24, 2026, as well as Korsana's subsequent filings with the SEC, including Current Reports on Form 8-K), as well as risk factors associated with companies, such as Korsana, that operate in the biopharma industry. Should one or more of these risks or uncertainties materialize, or should any of Korsana’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this communication, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Korsana does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements. This press release does not purport to summarize all of the conditions, risks and other attributes of an investment in Korsana.

Investor and Media Contact: Eva Stroynowski [email protected] [email protected]

1Pro-forma cash as of June 30, 2026, including PIPE, net of projected deal costs.

Search Investors

In connection with the Merger, Cyclerion held an annual meeting of Cyclerion shareholders on August 26, 2026 (the “Shareholder Meeting”), at which the Company’s shareholders voted on the proposals set forth below relating to the Merger Agreement. The proposals are described in detail in the Company’s definitive proxy statement/prospectus filed on Form S-4 with the Securities and Exchange Commission (the “SEC”), most recently amended on July 22, 2026 and declared effective on July 24, 2026 (as amended, the “Proxy Statement”) and first mailed to the Company’s shareholders on July 24, 2026. The final voting results regarding each proposal are set forth below. There were 4,681,351 shares of the Company’s common stock outstanding and entitled to vote on July 17, 2026, the record date for the Shareholder Meeting, and 3,896,779 shares of the Company’s common stock were represented in person or by proxy at the Shareholder Meeting, which number constituted a quorum. Proposal No.

Prompts

Korsana Biosciences, Inc. (ticker KRSA), listed in United States.

Company History

Date Change Detail
Sep 10, 2026 Renamed CYCLERION THERAPEUTICS, INC. → Korsana Biosciences, Inc.
— Former tickers CYCN

ETFs Holding Korsana Biosciences, Inc.

ETF Weight in ETF Shares Market value As of
DFSU 0.00% 474 $ 14.827K Nov 12, 2026
DXUV 0.00% 470 $ 14.702K Nov 12, 2026
DFAC 0.00% 312 $ 9,759.36 Nov 12, 2026
DCOR 0.00% 106 $ 3,315.68 Nov 12, 2026